+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of AZD1163, a novel bispecific antibody, in adults with moderately-to-severely active rheumatoid arthritis RA. AZD1163 targets enzymes involved in protein citrullination, which leads to the production of harmful antibodies in RA. This Phase II, randomized, double-blind, placebo-controlled study focuses on adults with positive anti-citrullinated peptide antibodies ACPA who are already receiving standard treatments. Participants will be randomly assigned to one of four groups to receive subcutaneous injections of either one of three doses of AZD1163 or a placebo, all combined with their standard care including conventional synthetic disease-modifying antirheumatic drugs csDMARDs or tumor necrosis factor inhibitors TNFi with or without csDMARDs. The treatment period lasts 24 weeks, followed by a safety follow-up phase of 28 weeks. During the study, participants will undergo assessments including measures of disease activity using scores such as DAS28-CRP at 12 weeks. Additional evaluations will monitor response criteria, clinical disease activity indices, and the pharmacokinetics and immunogenicity of AZD1163 up to 24 weeks and during follow-up. Safety and efficacy will be closely monitored throughout the treatment and follow-up periods, with total participation lasting approximately 52 weeks.

Age: 18Years +All GendersPhase 2
147 locations
E

Actively Recruiting

Researchers are evaluating the safety and effects of ritlecitinib, a medicine taken by mouth, for adults with chronic spontaneous urticaria CSU that is not well controlled by antihistamines. CSU causes itchy hives and swelling beneath the skin without a clear cause. This phase 2 study compares two doses of ritlecitinib, 50 mg and 100 mg once daily, against a placebo in adults diagnosed with CSU for at least three months. Participants will be randomly assigned to receive either 50 mg or 100 mg of ritlecitinib or a placebo daily for 12 weeks Period A. After this, those on ritlecitinib continue their dose for another 12 weeks Period B, while those on placebo switch to 100 mg of ritlecitinib. The study will compare the effects and safety of these treatments over the two 12-week periods. During about 8 months of participation, individuals will make up to 9 visits to the study site for various tests including physical exams, hearing tests, blood tests, X-rays, and ECGs. They will also complete daily electronic diaries about their urticaria symptoms. Researchers will measure changes in symptom scores and monitor any side effects throughout the study to assess safety and treatment effects.

Age: 18Years +All GendersPhase 2
77 locations
P

Actively Recruiting

Researchers are evaluating whether tralokinumab given as subcutaneous injections along with topical corticosteroids TCS is safe and effective for treating moderate-to-severe atopic dermatitis AD in children and infants. The trial involves two age groups children aged 2 to under 12 years and infants aged 6 months to under 2 years. Children are randomized to receive either tralokinumab plus TCS or placebo plus TCS, while infants receive open-label tralokinumab plus TCS. This Phase 3 trial will last up to four years with visits every two weeks during the first year and every six weeks thereafter, including some phone visits.

Age: 6Months - 11YearsAll GendersPhase 3
72 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of NNC0487-0111 in adults with excess body weight and knee osteoarthritis. This phase 3 study compares NNC0487-0111 to a placebo to determine its impact on weight loss and knee pain reduction. Participants have symptomatic knee osteoarthritis confirmed by clinical and radiographic criteria and experience knee pain for more than 90 days. Participants receive subcutaneous injections of either NNC0487-0111 or placebo once weekly. Both groups follow a reduced-calorie diet and increased physical activity as part of the treatment plan. The study uses pre-filled pen-injectors for administration at one of three body sites thigh, abdomen, or upper arm. The treatment period lasts up to 80 weeks. During the study, participants will be monitored through various assessments including body weight, knee pain using the WOMAC pain score, physical function, blood pressure, cholesterol levels, blood glucose, and use of pain medications. Safety will be tracked by recording adverse events up to 84 weeks. Participants will complete questionnaires and have clinical evaluations at regular intervals throughout the trial.

Age: 18Years +All GendersPhase 3
81 locations
E

Actively Recruiting

Researchers are evaluating the combination of cefazolin with ertapenem for treating methicillin-susceptible Staphylococcus aureus MSSA bacteremia, a serious bloodstream infection. This phase 2 randomized controlled trial explores whether adding ertapenem to cefazolin can improve clinical outcomes compared to cefazolin alone. MSSA bacteremia causes significant mortality, and current treatments have room for improvement, prompting this study as a sub-study of the SNAP trial. Participants will receive either ertapenem intravenously 1g daily infused over 2 hours for 5 days alongside cefazolin or a saline placebo infusion alongside cefazolin. The ertapenem targets a different bacterial protein than cefazolin, potentially enhancing treatment effectiveness. The study involves randomized assignment to one of two groups ertapenem plus cefazolin or placebo plus cefazolin. During the trial, participants will be assessed for clinical success by Day 5, and monitored up to 90 days for outcomes including blood culture clearance, clinical improvement, length of hospital stay, mortality, infections like C. difficile, and kidney injury. Safety monitoring includes tracking seizures and new bacterial colonization. Follow-up visits and evaluations will help researchers measure the impact of the combination therapy over time.

Age: 18Years - 100YearsAll GendersPhase 2
8 locations
P

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of subcutaneous treatment with lunsekimig compared with placebo in adults aged 40 to 80 years who have inadequately controlled Chronic Obstructive Pulmonary Disease COPD characterized by an eosinophilic phenotype. This Phase 2bPhase 3 study includes participants with a history of COPD, ongoing symptoms despite treatment, and specific lung function and blood eosinophil criteria. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a placebo group. All treatments are given as subcutaneous injections during a 48-week treatment period. The study consists of a screening period up to 4 weeks, followed by the 48-week randomized treatment, and then an approximately 8-week follow-up period, totaling up to 60 weeks of participation. During the study, participants will undergo lung function tests, symptom and quality of life questionnaires, and blood tests to monitor eosinophil counts and drug levels. The main outcome measured is the annualized rate of moderate-to-severe COPD exacerbations over 48 weeks. Additional assessments include changes in lung function, symptom scores, safety events, and antibody development. Safety monitoring continues through the follow-up period after treatment ends.

Age: 40Years - 80YearsAll GendersPhase 3
314 locations
I

Actively Recruiting

The trial investigates treatments for bloodstream infection caused by Staphylococcus aureus SAB, which can be life-threatening with a 15-30% death rate within three months. This international, multi-center randomized adaptive platform trial aims to find the best treatment options to reduce mortality within 90 days of infection. The trial adapts over time by assigning more patients to treatments that show better outcomes and removing less effective options. Participants receive various antibiotic treatments depending on their group. These include intravenous vancomycin or daptomycin, flucloxacillin or cloxacillin, cefazolin, or benzylpenicillin, with dosages adjusted for kidney function or illness severity. Some receive adjunctive drugs like clindamycin, and others may switch from intravenous to oral antibiotics if eligible after 7 or 14 days. Additionally, some participants undergo PETCT scans as part of the study. During the study, participants are monitored closely with blood cultures, temperature checks, and clinical assessments to track infection clearance and complications. Researchers measure all-cause mortality at 90 days as the primary outcome, along with other outcomes such as survival at earlier time points, hospital stay length, microbiological treatment failure, serious reactions, and antibiotic use. Safety and health economic data are also collected to evaluate treatments comprehensively throughout the trial.

All AgesAll GendersPhase 4
161 locations